Vanda Announces Listing of a New HETLIOZ® Patent in the FDA Orange Book
Retrieved on:
Thursday, September 20, 2018
WASHINGTON, Sept. 20, 2018 /PRNewswire/ --Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that a HETLIOZpatent, number 10,071,977('977 patent), is now listed in theU.S.
Key Points:
- WASHINGTON, Sept. 20, 2018 /PRNewswire/ --Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that a HETLIOZpatent, number 10,071,977('977 patent), is now listed in theU.S.
- Food and Drug Administrationpublication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book.
- The '977 patent was issued by the United States Patent and Trademark Office onSeptember 11, 2018and expires in February 2035.
- Prior to this newly listed '977 patent, the HETLIOZOrange Book listed patent with the latest expiry date was set to expire in May 2034.